Aggressive After Brain Anyeurysm

AGAINST GOLIATH DAVID

Quando incontrai Augusto Odone, lui mi chiese di prendere in mano il Comitato Italiano Mielina. Era stato lui a farlo nascere in Italia e in tutto il mondo. L’obiettivo era quello di continuare a promuovere la ricerca farmacologia per offrire una speranza ai bambini malati di adrenoleucodistrofia e ai loro genitori. Lorenzo era malato di una malattia rara e demielinizzante. Augusto aveva contribuito a combatterla “scoprendo” l’olio che prende il name of his son and still allows you to slow its progression.

accepted well aware of the difficulties in this field is the lack of "numbers" needed to obtain adequate funding dedicated to the development of medicines. An almost impossible challenge, against all laws of the market: get a huge amount of money necessary for the development of molecular medicines that will never bring the profit necessary to cover the cost of research and production and to involve the pharmaceutical industry, the only repositories of knowledge necessary to go from an idea to a product administration. In

help came the global economic crisis. He questioned certain rules of profit "at all costs" and led to the development of "Corporate Social Responsibility." Based on this new "ethical" business, the international community is now asking companies to take responsibility for the problems of adaptation and humanization derivantidalla their activities.

CEOs and managers of multinational companies should also begin to realize that the historical and current economic situation has led to new forms of entrepreneurship: often fueled by public money, they can collect the collaboration of entities universities, hospitals, the same industry, non-profit consortium. For the "business" of the drug, the objective must be to obtain an effective medicine to combat disease but little interest from the point of view.

What the industry "health" is still a problem with broad spectrum. The search for profit puts the moral and ethical questions. One wonders if the "attention disorder" (Add) and "hyperactivity (ADHD) have been crafted to achieve new market shares. It is assumed that scientific research should be driven by pharmaceutical interests which guide scientists. There is indignant the fact that millions of people can not afford the costs of therapy and do not have a state health system. You agree that, due to a patent or intellectual property, life-saving molecules have high costs and often inaccessible.

Certainly this is the time when "Big Pharma" (the giant accused of running cartels and interests that go beyond the welfare of the patient and whose profit exceeds that of the top 490 corporations combined) could dispel any gossip dedicating a small percentage of its profits to various children much less fortunate than us all.

Massimiliano Fanni Canelles